Quad Pill for HIV Appears Safe in Renal Disease (CME/CE)

Quad Pill for HIV Appears Safe in Renal Disease (CME/CE)

HIV patients with mild to moderate renal impairment appear to tolerate treatment with a combination tablet that contains drugs known to impact kidney function, a phase III, open-label, two-cohort study found.

The treatment group receiving the four-drug combination of elvitegravir, cobicistat, tenofovir DF, and emtricitabine, branded as Stribild, saw a small impact on estimated creatinine clearance (eCCr), but the change rapidly plateaued and may not be clinically meaningful, Frank Post, MD, a reader in HIV at Kings College Hospital in London, told MedPage Today